Current and evolving immunosuppressive regimens in kidney transplantation

American Journal of Kidney Diseases

Volumn 47, Issue 4 SUPPL. 2, 2006, Pages

  Gaston, Robert S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Antibody induction; Corticosteroids; Cyclosporine (CsA); Kidney transplant; Mycophenolate mofetil (MMF); Sirolimus (SRL); Tacrolimus (TAC)

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; GINGIVA HYPERPLASIA; HEALTH SERVICE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; MEDICAL RESEARCH; MOUTH ULCER; NEPHROTOXICITY; PNEUMONIA; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

EID: 33645304016     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.12.047     Document Type: Article

References (113)

1. Astellas Pharma US Inc Prograf Package Insert 2005 Astellas Pharma US Inc Deerfield, IL
2. Novartis Pharmaceuticals Corp Neoral Package Insert 2004 Novartis Pharmaceuticals Corp East Hanover, NJ
3. G.M. Danovitch Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients Transplant Proc 31 1999 S2 S6 (suppl 8A)
4. F. Vincenti, S.C. Jensik, R.S. Filo, J. Miller, J. Pirsch A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation Evidence for improved allograft survival at five years Transplantation 73 2002 775 782
5. R. Margreiter European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation A randomised multicentre study Lancet 359 2002 741 746
6. B.K. Krämer, G. Montagnino, D. del Castillo Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation 2 Year follow-up results Nephrol Dial Transplant 20 2005 968 973
7. B. Kaplan, J.D. Schold, H.U. Meier-Kriesche Long-term graft survival with Neoral and tacrolimus A paired kidney analysis J Am Soc Nephrol 14 2003 2980 2984
8. D.B. Kaufman, R. Shapiro, M.R. Lucey, W.S. Cherikh, R.T. Bustami, D.B. Dyke Immunosuppression Practice and trends Am J Transplant 4 2004 S38 S53 (suppl 9)
9. 2004 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI. Available at: http://www.optn.org/AR2004/default.htm. Accessed October 12, 2005
10. R. Oberbauer, H. Kreis, R.W. Johnson Rapamune Maintenance Regimen Study Group Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients 2-Year results of the Rapamune Maintenance Regimen Study Transplantation 76 2003 364 370
11. T. Gonwa, R. Mendez, H.C. Yang Prograf Study Group Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation Results at 6 months Transplantation 75 2003 1213 1220
12. C. Johnson, N. Ahsan, T. Gonwa Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation Transplantation 69 2000 834 841
13. R. Mendez, T. Gonwa, H.C. Yang A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation Results at 1 year Transplantation 80 2005 303 309
14. N. Ahsan, C. Johnson, T. Gonwa Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine vs cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation Results at 2 years Transplantation 72 2001 245 250
15. T. Gonwa, C. Johnson, N. Ahsan Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation Results at three years Transplantation 75 2003 2048 2053
16. T. van Gelder, J. Klupp, M.J. Barten, U. Christians, R.E. Morris Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid Ther Drug Monit 23 2001 119 128
17. Fitzsimmons WE, First MR, Gao J. The relationship of tacrolimus blood levels to efficacy and adverse events in kidney transplant patients treated with mycophenolate mofetil or sirolimus (abstr). Presented at the Third International Congress on Immunosuppression, December 9, 2004, San Diego, CA
18. G.M. Danovitch Immunosuppressive medications and protocols for kidney transplantation G.M. Danovitch Handbook of Kidney Transplantation ed 4 2005 Lippincott Williams & Wilkins Philadelphia, PA 72 134
19. International Neoral Renal Transplantation Study Group Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation Am J Transplant 2 2002 148 156
20. J.D. Pirsch, J. Miller, M.H. Deierhoi, F. Vincenti, R.S. Filo FK506 Kidney Transplant Study Group A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation Transplantation 63 1997 977 983
21. R. Trompeter, G. Filler, N.J.A. Webb Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation Pediatr Nephrol 17 2002 141 149
22. G. Filler, N.J.A. Webb, D.V. Milford Four-year data after pediatric renal transplantation A randomized trial of tacrolimus vs cyclosporin microemulsion Pediatr Transplant 9 2005 498 503
23. A. Humar, W.D. Payne, D.E. Sutherland, A.J. Matas Clinical determinants of multiple acute rejection episodes in kidney transplant recipients Transplantation 69 2000 2357 2360
24. S. Hariharan, C.P. Johnson, B.A. Bresnahan, S.E. Taranto, M.J. McIntosh, D. Stablein Improved graft survival after renal transplantation in the United States, 1988 to 1996 N Engl J Med 342 2000 605 612
25. H.U. Meier-Kriesche, J.D. Schold, T.R. Srinivas, B. Kaplan Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era Am J Transplant 4 2004 378 383
26. B.L. Kasiske, R.S. Gaston, S. Gourishankar Long-term deterioration of kidney allograft function Am J Transplant 5 2005 1405 1414
27. S. Hariharan, M.A. McBride, W.S. Cherikh, C.B. Tolleris, B.A. Bresnahan, C.P. Johnson Post-transplant renal function in the first year predicts long-term kidney transplant survival Kidney Int 62 2002 311 318
28. H.U. Meier-Kriesche, R. Baliga, B. Kaplan Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation Transplantation 75 2003 1291 1295
29. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154 2169
30. B.J. Nankivell, R.J. Borrows, C.L. Fung, P.J. O'Connell, R.D. Allen, J.R. Chapman The natural history of chronic allograft nephropathy N Engl J Med 349 2003 2326 2333
31. S. Gourishankar, L.G. Hunsicker, G.S. Jhangri, S.M. Cockfield, P.F. Halloran The stability of the glomerular filtration rate after renal transplantation is improving J Am Soc Nephrol 14 2003 2387 2394
32. G. Ciancio, G.W. Burke, J.J. Gaynor A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year Transplantation 77 2004 252 258
33. M.R. Weir, M.T. Ward, S.A. Blahut Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy Kidney Int 59 2001 1567 1573
34. US Renal Data System USRDS 2004 Annual Data Report 2004 The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease Bethesda, MD
35. Jensik SC and the FK506 Kidney Transplant Study Group Tacrolimus (FK506) in kidney transplantation Three-year survival results of the US multicenter, randomized, comparative trial Transplant Proc 30 1998 1216 1218
36. B.K. Krämer, C. Zülke, M.C. Kammerl European Tacrolimus vs Cyclosporine Microemulsion Renal Transplantation Group Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation Am J Transplant 3 2003 982 987
37. I.H. Klein, A. Abrahams, T. van Ede, R.J. Hene, H.A. Koomans, G. Ligtenberg Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects Transplantation 73 2002 732 736
38. G. Ligtenberg, R.J. Hené, P.J. Blankestijn, H.A. Koomans Cardiovascular risk factors in renal transplant patients Cyclosporin A versus tacrolimus J Am Soc Nephrol 12 2001 368 373
39. M.A. Artz, J.M.M. Boots, G. Ligtenberg Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile Am J Transplant 4 2004 937 945
40. B.L. Kasiske, J.J. Snyder, D. Gilbertson, A.J. Matas Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178 185
41. F.G. Cosio, T.E. Pesavento, S. Kim, K. Osei, M. Henry, R.M. Ferguson Patient survival after renal transplantation: IV. Impact of post-transplant diabetes Kidney Int 62 2002 1440 1446
42. F.G. Cosio, Y. Kudva, M. van der Velde New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation Kidney Int 67 2005 2415 2421
43. R.S. Gaston, G. Basadonna, F.G. Cosio National Kidney Foundation Task Force on Diabetes and Transplantation: Transplantation in the diabetic patient with advanced chronic kidney disease: A task force report Am J Kidney Dis 44 2004 529 542
44. J. Romagnoli, F. Citterio, P. Violi, G. Nanni, M. Castagneto Posttransplant diabetes mellitus after kidney transplantation with different immunosuppressive agents Transplant Proc 36 2004 690 691
45. K. Tamura, T. Fujimura, T. Tsutsumi Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell Transplantation 59 1995 1606 1613
46. J.B. Redmon, L.K. Olson, M.B. Armstrong Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells J Clin Invest 98 1996 2786 2793
47. R.S. Woodward, M.A. Schnitzler, J. Baty Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients Am J Transplant 3 2003 590 598
48. K. Tanabe Calcineurin inhibitors in renal transplantation What is the best option? Drugs 63 2003 1535 1548
49. N.B. Bouchta, L. Ghisdal, D. Abramowicz Conversion from tacrolimus to cyclosporine is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation Transplant Proc 37 2005 1857 1860
50. A. Teutonico, P.F. Schena, S. Di Paolo Glucose metabolism in renal transplant recipients Effect of calcineurin inhibitor withdrawal and conversion to tacrolimus J Am Soc Nephrol 16 2005 3128 3135
51. C. Teixeira de Barros, J. Cabrita Noncompliance with immunosuppressive therapy Prevalence and determinants Transplant Proc 32 2000 2633
52. Novartis Pharmaceuticals Corp Sandimmune Package Insert 2004 Novartis Pharmaceuticals Corp East Hanover, NJ
53. R. Margreiter, E. Pohanka, V. Sparacino, H. Sperschneider, U. Kuzendorf Large European study of the switch to tacrolimus for cyclosporine-related side effects Am J Transplant 2 2002 S405A (suppl 3; abstr 1060)
54. M. Kohnle, P. Lutkes, U. Zimmermann, T. Philipp, U. Heemann Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia Transplant Proc 31 1999 S44 S45 (suppl 7A)
55. R. Shapiro, M.L. Jordan, V.P. Scantlebury Alopecia as a consequence of tacrolimus therapy Transplantation 65 1998 1284
56. P. Halloran, T. Mathew, S. Tomlanovich, C. Groth, L. Hooftman, C. Barker International Mycophenolate Mofetil Renal Transplant Study Groups Mycophenolate mofetil in renal allograft recipients A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection Transplantation 63 1997 39 47
57. Roche Pharmaceuticals CellCept Package Insert 2004 Roche Pharmaceuticals Nutley, NJ
58. H.W. Sollinger, M.H. Deierhoi, F.O. Belzer, A.G. Diethelm, R.S. Kauffman RS-61443 - A phase I clinical trial and pilot rescue study Transplantation 53 1992 428 432
59. J.F. Neylan US Renal Transplant Mycophenolate Mofetil Study Group Immunosuppressive therapy in high-risk transplant patients Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients Transplantation 64 1997 1277 1282
60. H.U. Meier-Kriesche, A.O. Ojo, A.B. Leichtman Interaction of mycophenolate mofetil and HLA matching on renal allograft survival Transplantation 71 2001 398 401
61. T. van Gelder, L.B. Hilbrands, Y. Vanrenterghem A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 1999 261 266
62. A.K. Tsaroucha, K. Zucker, V. Esquenazi, L. de Faria, J. Miller, A.G. Tzakis Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and Cellcept combination therapy Transpl Immunol 8 2000 143 146
63. K. Zucker, A. Rosen, A. Tsaroucha Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy Transplant Proc 29 1997 334 336
64. S.M. Flechner, D. Goldfarb, C. Modlin Kidney transplantation without calcineurin inhibitor drugs A prospective, randomized trial of sirolimus versus cyclosporine Transplantation 74 2002 1070 1076
65. W.M. Bennett Immunosuppression with mycophenolic acid One size does not fit all J Am Soc Nephrol 14 2003 2414 2416
66. Haggan El, M. Ficheux, D. Debruyne Area-under-curve of mycophenolic acid in stable kidney transplant patients receiving sirolimus versus cyclosporine Am J Transplant 5 2005 S541 (suppl 11; abstr 1512)
67. R.M. van Hest, R.A. Mathot, A.G. Vulto, T. van Gelder Monitoring mycophenolic acid to optimize mycophenolate mofetil therapy What to measure and how often Am J Transplant 5 2005 S540 (suppl 11; abstr 1510)
68. M. Salvadori, H. Holzer, A. de Mattos The ERL B301 Study Groups Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients Am J Transplant 4 2004 231 236
69. H. Sollinger Enteric-coated mycophenolate sodium Therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients Transplant Proc 36 2004 S517 S520 (suppl 2S)
70. B.D. Kahan Rapamune US Study Group Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection A randomised multicentre study Lancet 356 2000 194 202
71. A.S. MacDonald RAPAMUNE Global Study Group A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 71 2001 271 280
72. H.U. Meier-Kriesche, B.J. Steffen, A.H. Chu Sirolimus with Neoral versus mycophenolate mofetil with Neoral is associated with decreased renal allograft survival Am J Transplant 4 2004 2058 2066
73. S.M. Flechner, S.M. Kurian, K. Solez De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years Am J Transplant 4 2004 1776 1785
74. R. Oberbauer, G. Segoloni, J.M. Campistol Rapamune Maintenance Study Group Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation Transpl Int 18 2005 22 28
75. Wyeth Pharmaceuticals Inc Rapamune Package Insert 2005 Wyeth Pharmaceuticals Inc Philadelphia, PA
76. R.W.G. Johnson, H. Kreis, R. Oberbauer, C. Brattstrom, K. Claesson, J. Eris Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777 786
77. H. Kreis, R. Oberbauer, J.M. Campistol Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal J Am Soc Nephrol 15 2004 809 817
78. B. Kaplan, J. Schold, T. Srinivas Effect of sirolimus withdrawal in patients with deteriorating renal function Am J Transplant 4 2004 1709 1712
79. G. Ciancio, G.W. Burke, J.J. Gaynor A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. I. Drug interactions and rejection at 1 year Transplantation 77 2004 244 251
80. H.U. Meier-Kriesche, J.D. Schold, T.R. Srinivas, R.J. Howard, S. Fujita, B. Kaplan Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus Am J Transplant 5 2005 2273 2280
81. V. Bumbea, D. Ribes, N. Kamar Outcome of renal-transplant (RT) patients switched from calcineurin inhibitors (CNIs) to sirolimus (SRL) for chronic allograft dysfunction (CAD) Am J Transplant 5 2005 S463A (suppl 11; abstr 1202)
82. F. Diekmann, K. Budde, F. Oppenheimer, L. Fritsche, H.H. Neumayer, J.M. Campistol Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction Am J Transplant 4 2004 1869 1875
83. G. Stallone, A. Schena, B. Infante Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317 1323
84. L.A. Szczech, J.A. Berlin, S. Aradhye, R.A. Grossman, H.I. Feldman Effect of anti-lymphocyte induction therapy on renal allograft survival A meta-analysis Am Soc Nephrol 8 1997 1771 1777
85. 2003 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1993-2002. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI. Available at: http://www.optn.org/AR2003/default.htm. Accessed October 12, 2005
86. B. Nashan, R. Moore, P. Amlot, A.-G. Schmidt, K. Abeywickrama, J.-P. Soulillou CHIB 201 International Study Group Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients Lancet 350 1997 1193 1198
87. F. Vincenti, R. Kirkman, S. Light Daclizumab Triple Therapy Study Group Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation N Engl J Med 338 1998 161 165
88. S. Bunnapradist, A. Daswani, S.K. Takemoto Patterns of administration of antibody induction therapy and their associated outcomes Clin Transpl 2002 351 358
89. G. Mourad, V. Garrigue, J.-P. Squifflet Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression Transplantation 72 2001 1050 1055
90. D.C. Brennan, K. Flavin, J.A. Lowell A randomized, double-blind comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients Transplantation 67 1999 1011 1018
91. Novartis Pharmaceuticals Corp Simulect Package Insert 2003 Novartis Pharmaceuticals Corp East Hanover, NJ
92. T.M. Chapman, G.M. Keating Basiliximab A review of its use as induction therapy in renal transplantation Drugs 63 2003 2803 2835
93. G. Mourad, L. Rostaing, C. Legendre, V. Garrigue, E. Thervet, D. Durand Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids Transplantation 78 2004 584 590
94. D.C. Brennan Thymoglobulin Induction Study Group Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients Expanded results from a prospective, randomized, multicenter trial Am J Transplant 3 2003 S438A S439A (suppl 5; abstr 1121)
95. Roche Pharmaceuticals Zenapax Package Insert 2003 Roche Pharmaceuticals Nutley, NJ
96. D. Abramowicz, Y. Vanrenterghem, J.-P. Squifflet Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients A multicenter, prospective, pilot trial Clin Transplant 19 2005 475 482
97. H.U. Meier-Kriesche, H. Kaza, S.S. Palekar The effect of daclizumab in a high-risk renal transplant population Clin Transplant 14 2000 509 513
98. F. Vincenti, Y. Vanrenterghem, B. Nashan The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 Month results Am J Transplant 5 2005 539 540 (suppl 11; abstr 1507)
99. G. Ciancio, G.W. Burke, J.J. Gaynor The use of Campath-1H as induction therapy in renal transplantation Preliminary results Transplantation 78 2004 426 433
100. C.J. Watson, J.A. Bradley, P.J. Friend Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation - Efficacy and safety at five years Am J Transplant 5 2005 1347 1353
101. R. Calne, S.D. Moffatt, P.J. Friend Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients Transplantation 68 1999 1613 1616
102. R. Shapiro, A. Basu, H. Tan Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath J Am Coll Surg 200 2005 505 515
103. S.J. Knechtle, L.A. Fernandez, J.D. Pirsch Campath-1H in renal transplantation The University of Wisconsin experience Surgery 136 2004 754 760
104. D.B. Kaufman, J.R. Leventhal, D. Axelrod, L.G. Gallon, M.A. Parker, F.P. Stuart Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation Comparison with basiliximab induction - Long-term results Am J Transplant 5 2005 2539 2548
105. L. Rostaing, D. Cantarovich, G. Mourad CARMEN Study Group Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation Transplantation 79 2005 807 814
106. N. Ahsan, D. Hricik, A. Matas Steroid Withdrawal Study Group Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study Transplantation 68 1999 1865 1874
107. R. Kandaswamy, J.K. Melancon, T. Dunn A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - An interim analysis Am J Transplant 5 2005 1529 1536
108. E.S. Woodle Fujisawa Steroid Withdrawal Study Group A randomized, double blinded, placebo controlled trial of early corticosteroid cessation versus chronic corticosteroid maintenance therapy Am J Transplant 5 2005 S540A S541A (suppl 11; abstr 1511)
109. B.M. Hall, D.J. Tiller, I. Hardie Comparison of three immunosuppressive regimens in cadaver renal transplantation Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine N Engl J Med 318 1988 1499 1507
110. M.P. Gallagher, B. Hall, J. Craig Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry: A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-Year results Transplantation 78 2004 1653 1660
111. H. Kreis, J.-M. Cisterne, W. Land Sirolimus European Renal Transplant Study Group Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients Transplantation 69 2000 1252 1260
112. D. Glotz, B. Charpentier, D. Abramovicz 6 months preliminary results of a randomized trial comparing sirolimus (SRL) versus tacrolimus (FK) in 141 transplant patients receiving a cadaveric renal graft Am J Transplant 5 2005 S460A (suppl 11; abstr 1191)
113. P.I. Terasaki, M. Ozawa Predicting kidney graft failure by HLA antibodies A prospective trial Am J Transplant 4 2004 438 443